Ind-Swift Laboratories Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Navrattan Munjal

İcra Kurulu Başkanı

₹30.3m

Toplam tazminat

CEO maaş yüzdesi	99.9%
CEO görev süresi	29.8yrs
CEO sahipliği	1.6%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	5.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Navrattan Munjal'un ücretlendirmesi Ind-Swift Laboratories'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	₹4b
Jun 30 2024	n/a	n/a	₹4b
Mar 31 2024	₹30m	₹30m	₹4b
Dec 31 2023	n/a	n/a	₹432m
Sep 30 2023	n/a	n/a	₹513m
Jun 30 2023	n/a	n/a	₹450m
Mar 31 2023	₹36m	₹36m	₹476m
Dec 31 2022	n/a	n/a	₹113m
Sep 30 2022	n/a	n/a	-₹2m
Jun 30 2022	n/a	n/a	-₹11m
Mar 31 2022	₹36m	₹36m	-₹21m
Dec 31 2021	n/a	n/a	₹301m
Sep 30 2021	n/a	n/a	₹256m
Jun 30 2021	n/a	n/a	₹111m
Mar 31 2021	₹33m	₹33m	-₹31m
Dec 31 2020	n/a	n/a	₹277m
Sep 30 2020	n/a	n/a	₹77m
Jun 30 2020	n/a	n/a	-₹111m
Mar 31 2020	₹30m	₹30m	-₹212m
Dec 31 2019	n/a	n/a	-₹734m
Sep 30 2019	n/a	n/a	-₹211m
Jun 30 2019	n/a	n/a	-₹35m
Mar 31 2019	₹18m	₹18m	₹289m
Mar 31 2018	₹18m	₹18m	₹220m

Tazminat ve Piyasa: Navrattan 'nin toplam tazminatı ($USD 349.45K ), Indian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 41.51K ).

Tazminat ve Kazançlar: Navrattan 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Navrattan Munjal (72 yo)

29.8yrs

Görev süresi

₹30,308,000

Tazminat

Mr. Navrattan R. Munjal has been a Managing Director of Ind-swift Laboratories Ltd. since March 29, 2001 and serves as its Chairman. He served as President of Indian Drug Manufacturers’ Association until J...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Navrattan Munjal	Chairman & MD	29.8yrs	₹30.31m	1.56% ₹ 88.0m
Himanshu Jain	Joint MD & Whole Time Director	21.6yrs	₹37.88m	0.69% ₹ 38.9m
Rishav Mehta	Executive Director	14.9yrs	₹15.16m	0.77% ₹ 43.7m
Sahil Munjal	President of Operations & Special Assignments and Executive Director	5yrs	₹17.92m	0.011% ₹ 646.4k
Sri Sharma	Non-Executive Independent Director	12.4yrs	₹186.75k	Veri yok
Ashwani Vig	Non-Executive Independent Director	5yrs	₹123.75k	Veri yok
Neerja Chathley	Non-Executive Independent Woman Director	5.8yrs	₹85.50k	Veri yok
Rajinder Gupta	Non-Executive Independent Director	3.7yrs	₹148.50k	Veri yok
Param Singh	Independent Director	less than a year	Veri yok	Veri yok

5.8yrs

Ortalama Görev Süresi

68yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 532305 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.8 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/02/11 09:14
Gün Sonu Hisse Fiyatı	2025/02/11 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2024/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Ind-Swift Laboratories Limited 1 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Hitesh Kuvelkar	First Global Stockbroking (P) Ltd.

Ind-Swift Laboratories Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Chief Financial Officer recently sold ₹4.2m worth of stock

Ind-Swift Laboratories Limited, Annual General Meeting, Sep 30, 2024

Ind-Swift Laboratories Limited Appoints Mr. Param Bir Singh as an Independent Director

Ind-Swift Laboratories Limited, Annual General Meeting, Sep 30, 2023

Group Head of Human Resources recently sold ₹3.3m worth of stock

Chief Accounts Officer recently sold ₹1.6m worth of stock

Recent updates

Second quarter 2025 earnings released: EPS: ₹0.07 (vs ₹5.36 in 2Q 2024)

Chief Financial Officer recently sold ₹4.2m worth of stock

Ind-Swift Laboratories Limited to Report Q3, 2025 Results on Feb 14, 2025

Ind-Swift Laboratories Limited, Annual General Meeting, Sep 30, 2024

First quarter 2025 earnings released: EPS: ₹0.16 (vs ₹2.92 in 1Q 2024)

Ind-Swift Laboratories Limited to Report Q1, 2025 Results on Aug 12, 2024

Investor sentiment improves as stock rises 24%

Ind-Swift Laboratories Limited Appoints Mr. Param Bir Singh as an Independent Director

Full year 2024 earnings released: EPS: ₹71.24 (vs ₹8.06 in FY 2023)

Ind-Swift Laboratories Limited to Report Q4, 2024 Results on May 13, 2024

New minor risk - Share price stability

Investor sentiment improves as stock rises 16%

Synthimed Labs Private Limited agreed to acquire API and CRAMS business of Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) and Essix Biosciences Limited.

Third quarter 2024 earnings released: EPS: ₹3.29 (vs ₹4.65 in 3Q 2023)

Ind-Swift Laboratories Limited to Report Q3, 2024 Results on Feb 12, 2024

Second quarter 2024 earnings released: EPS: ₹5.36 (vs ₹4.29 in 2Q 2023)

Ind-Swift Laboratories Limited to Report Q2, 2024 Results on Nov 07, 2023

Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) agreed to acquire Ind-Swift Limited (BSE:524652).

Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) agreed to acquire Ind-Swift Limited (BSE:524652).

Synthimed Labs Private Limited agreed to acquire API and CRAMS business of Ind-Swift Laboratories Limited for INR 16.5 billion.

Ind-Swift Laboratories Limited, Annual General Meeting, Sep 30, 2023

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

First quarter 2024 earnings released: EPS: ₹2.92 (vs ₹3.36 in 1Q 2023)

Ind-Swift Laboratories Limited to Report Q1, 2024 Results on Aug 09, 2023

Group Head of Human Resources recently sold ₹3.3m worth of stock

Investor sentiment improves as stock rises 15%

Chief Accounts Officer recently sold ₹1.6m worth of stock

Full year 2023 earnings released: EPS: ₹8.06 (vs ₹0.36 loss in FY 2022)

Full year 2023 earnings released: EPS: ₹8.06 (vs ₹0.36 loss in FY 2022)

Insufficient new directors

Third quarter 2023 earnings released: EPS: ₹4.65 (vs ₹2.71 in 3Q 2022)

Insider recently sold ₹1.2m worth of stock

Second quarter 2023 earnings released: EPS: ₹4.29 (vs ₹4.14 in 2Q 2022)

Insider recently sold ₹1.6m worth of stock

Ind-Swift Laboratories Limited to Report Fiscal Year 2023 Results on May 30, 2023

First quarter 2023 earnings released: EPS: ₹3.36 (vs ₹3.18 in 1Q 2022)

Ind-Swift Laboratories Limited, Annual General Meeting, Sep 30, 2022

Ind-Swift Laboratories Limited to Report Q1, 2023 Results on Aug 10, 2022

Full year 2022 earnings released: ₹0.36 loss per share (vs ₹0.53 loss in FY 2021)

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS ₹4.14 (vs ₹1.68 in 2Q 2021)

Investor sentiment deteriorated over the past week

Soft Air General Trading LLC agreed to acquire Ind-Swift Middle East FZ-LLC from Ind-Swift Laboratories Limited (BSE:532305) for approximately $2 million.

First quarter 2022 earnings released: EPS ₹3.18 (vs ₹0.77 in 1Q 2021)

High number of new directors

Full year 2021 earnings released: ₹0.53 loss per share (vs ₹4.28 loss in FY 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Insider recently sold ₹1.0m worth of stock

Independent Director has left the company

Insider recently sold ₹1.4m worth of stock

Investor sentiment improved over the past week

New 90-day high: ₹86.75

Insider recently sold ₹2.1m worth of stock

Third quarter 2021 earnings released: EPS ₹1.95 (vs ₹1.90 loss in 3Q 2020)

Ind-Swift Laboratories Limited to Report Q3, 2021 Results on Feb 12, 2021

Investor sentiment deteriorated over the past week

Ind-Swift Labs' Promoters Reportedly Sound Out PEs to Sell Their Stake

Senior Vice President of Procurement recently sold ₹2.7m worth of stock

Investor sentiment improved over the past week

New 90-day high: ₹70.80

Insider recently sold ₹1.2m worth of stock

Senior Vice President of QA recently sold ₹1.4m worth of stock